AVDL · As filed with the SEC

Avadel Pharmaceuticals cash flow statement, by quarter

The statement as Avadel Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS · USD thousands

USD thousands	Q3 2025^† 3 months ended Sep 30, 2025	Q2 2025^† 3 months ended Jun 30, 2025	Q1 2025 3 months ended Mar 31, 2025	Q4 2024^† 3 months ended Dec 31, 2024	Q3 2024^† 3 months ended Sep 30, 2024	Q2 2024^† 3 months ended Jun 30, 2024	Q1 2024 3 months ended Mar 31, 2024	Q4 2023^† 3 months ended Dec 31, 2023
Cash flows from operating activities:
Net income (loss)	20^†	9,665^†	(4,920)	(5,043)^†	(2,625)^†	(13,822)^†	(27,342)	(28,786)^†
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	1,115^†	1,068^†	825	668^†	1,035^†	437^†	541	(18)^†
Amortization of debt discount and debt issuance costs	—	—	—	0^†	0^†	0^†	0	0^†
Share-based compensation expense	4,919^†	5,327^†	4,183	4,126^†	5,410^†	5,462^†	5,389	3,518^†
Loss on extinguishment of debt	—	—	—	0^†	0^†	—	—	0^†
Other adjustments	(262)^†	(856)^†	70	224^†	156^†	(489)^†	(719)	1,611^†
Net changes in assets and liabilities
Accounts receivable	(1,813)^†	950^†	(7,484)	3,005^†	(3,725)^†	(10,685)^†	(10,589)	(5,864)^†
Inventories	(681)^†	(3,295)^†	(66)	(3,964)^†	(2,991)^†	(1,004)^†	(1,260)	(4,246)^†
Prepaid expenses and other current assets	842^†	612^†	(3,016)	2,031^†	(58)^†	4,525^†	(6,093)	76^†
Research and development tax credit receivable	—	—	—	—	—	468^†	(17)	(34)^†
Accounts payable & other current liabilities	2,289^†	999^†	1,779	(577)^†	(1,878)^†	(9,166)^†	7,528	(2,292)^†
Accrued expenses	(3,572)^†	1,859^†	218	6,744^†	196^†	6,069^†	3,415	6,271^†
Other assets and liabilities	(652)^†	(3,632)^†	179	659^†	(2,410)^†	36^†	(557)	(183)^†
Net cash provided by (used in) operating activities	22,205^†	12,697^†	(8,232)	7,873^†	(6,890)^†	(18,186)^†	(29,704)	(28,029)^†
Cash flows from investing activities:
Purchases of property and equipment	(9)^†	—	—	0^†	0^†	—	—	0^†
Proceeds from sales of marketable securities	11,800^†	28,130^†	17,808	28,952^†	90,994^†	88,769^†	119,066	61,638^†
Purchases of marketable securities	(5,224)^†	(36,203)^†	(5,491)	(14,039)^†	(86,064)^†	(78,219)^†	(97,679)	(33,710)^†
Net cash (used in) provided by investing activities	(8,433)^†	(8,254)^†	12,317	14,913^†	4,930^†	10,550^†	21,387	27,928^†
Cash flows from financing activities:
Proceeds received in advance of Series B Preferred Shares Issuance	—	—	—	—	—	—	0	—
Proceeds from issuance of shares off the at-the-market offering program	0^†	0^†	0	—	0^†	0^†	9,250	—
At-the-market offering program	—	—	—	0^†	0^†	—	—	0^†
Public offering	—	—	—	0^†	0^†	—	—	2^†
Proceeds from stock option exercises and employee share purchase plan	2,507^†	982^†	690	880^†	1,177^†	723^†	3,940	52^†
Payments for Notes	—	—	—	—	0^†	0^†	0	—
Payments for debt issuance costs	—	—	—	0^†	0^†	—	—	0^†
Proceeds from royalty purchase agreement	—	—	—	0^†	—	—	—	0^†
Net cash provided by financing activities	2,507^†	982^†	690	880^†	1,177^†	723^†	13,190	(21,111)^†
Effect of foreign currency exchange rate changes on cash and cash equivalents	132^†	1,607^†	224	(877)^†	518^†	(34)^†	(246)	568^†
Net change in cash and cash equivalents	16,411^†	7,032^†	4,999	22,789^†	(265)^†	(6,947)^†	4,627	(20,644)^†
Cash and cash equivalents at January 1,	63,402	56,370	51,371	28,582	28,847	35,794	31,167	51,811
Cash and cash equivalents at September 30,	79,813	63,402	56,370	51,371	28,582	28,847	35,794	31,167
Supplemental disclosures of cash flow information:
Interest paid	2,555^†	1,969^†	1,890	3,876^†	1,557^†	1,018^†	730	730^†
Income taxes refunded, net	—	—	—	—	—	—	—	0^†

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.